Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19205490 | TREATMENT OF FISTULA WITH BONE MARROW MESENCHYMAL STEM CELL DERIVED EXTRACELLULAR VESICLES | May 2025 | November 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 19055164 | Treatment for Chronic Kidney Disease | February 2025 | October 2025 | Abandon | 8 | 1 | 0 | No | No |
| 18933318 | COLLAGEN AND USE THEREOF | October 2024 | August 2025 | Allow | 10 | 1 | 1 | Yes | No |
| 18787118 | COMPOSITIONS AND METHODS OF PREPARING AIRWAY CELLS | July 2024 | January 2026 | Allow | 18 | 1 | 0 | No | No |
| 18786855 | ENGINEERING MECHANICALLY FUNCTIONAL HUMAN CARTILAGE AND METHOD OF MAKING SAME | July 2024 | March 2026 | Allow | 19 | 1 | 0 | No | No |
| 18679906 | COMPOSITIONS AND METHODS FOR OBTAINING ORGANOIDS | May 2024 | March 2025 | Allow | 10 | 1 | 0 | Yes | No |
| 18656253 | Perfusion Culturing Methods and Uses Thereof | May 2024 | April 2025 | Allow | 11 | 1 | 0 | No | No |
| 18622012 | ORGANOTYPIC DRG-PERIPHERAL NERVE CULTURE SYSTEM | March 2024 | March 2025 | Allow | 11 | 1 | 0 | Yes | No |
| 18606318 | METHOD OF FORMING A MYCOLOGICAL PRODUCT | March 2024 | April 2025 | Allow | 13 | 1 | 0 | No | No |
| 18603954 | SYSTEMS AND METHODS FOR MONITORING TISSUE SAMPLE PROCESSING | March 2024 | September 2025 | Allow | 18 | 1 | 1 | No | No |
| 18686912 | Depolymerization of a Polyhydroxyalkanoate and Recycling of Hydroxyalkonoate Monomer Obtained Thereby Via a Metabolic Process | February 2024 | January 2025 | Allow | 11 | 1 | 0 | No | No |
| 18441106 | Adherent Cell Culture Substrate Sampling Device | February 2024 | March 2025 | Allow | 14 | 1 | 0 | Yes | No |
| 18436701 | LOW SHEAR MICROFLUIDIC DEVICES AND METHODS OF USE AND MANUFACTURING THEREOF | February 2024 | May 2025 | Abandon | 15 | 1 | 0 | No | No |
| 18409181 | METHODS TO IMPROVE ORGAN VIABILITY | January 2024 | December 2024 | Allow | 12 | 1 | 0 | No | No |
| 18406886 | CYTOPHERESIS CARTRIDGES AND USE THEREOF | January 2024 | July 2025 | Allow | 18 | 1 | 0 | No | No |
| 18541238 | MULTISTRAIN POPULATION CONTROL SYSTEMS AND METHODS | December 2023 | January 2026 | Allow | 25 | 1 | 1 | Yes | No |
| 18535865 | TREATMENT OF VASCULOPATHY WITH PROSTACYCLIN AND MESENCHYMAL STEM CELLS | December 2023 | December 2024 | Allow | 12 | 1 | 0 | No | No |
| 18535745 | TREATMENT OF PULMONARY ARTERIAL HYPERTENSION WITH PROSTACYCLIN-TREATED ENDOTHELIAL PROGENITOR CELLS | December 2023 | January 2025 | Allow | 14 | 1 | 0 | No | No |
| 18512646 | Bioerodible Matrix for Tissue Involvement | November 2023 | April 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18389470 | ENGINEERED MATERIALS AND METHODS OF FORMING | November 2023 | July 2025 | Allow | 20 | 1 | 0 | Yes | No |
| 18387192 | METHOD OF ISOLATING MESENCHYMAL STEM CELLS FROM THE AMNIOTIC MEMBRANE OF THE UMBILICAL CORD, A MESENCHYMAL STEM CELL POPULATION ISOLATED FROM THE AMNIOTIC MEMBRANE OF THE UMBILICAL CORD AND A CELL CULTURE MEDIUM FOR ISOLATING MESENCHYMAL STEM CELLS FROM THE AMNIOTIC MEMBRANE OF THE UMBILICAL CORD | November 2023 | February 2025 | Allow | 16 | 1 | 0 | No | No |
| 18499761 | SYSTEMS AND METHODS FOR PERFORMING ANTIMICROBIAL SUSCEPTIBILITY TESTING | November 2023 | January 2025 | Allow | 14 | 1 | 0 | No | No |
| 18498807 | OIL OF MICROORGANISMS RICH IN DOCOSAHEXAENOIC ACID | October 2023 | March 2025 | Allow | 16 | 1 | 0 | No | No |
| 18553977 | PROCESS FOR THE PREPARATION OF A SUGAR PRODUCT AND A FERMENTATION PRODUCT | October 2023 | March 2026 | Allow | 29 | 1 | 0 | No | No |
| 18553487 | HYALURONIC ACID-PRODUCING RECOMBINANT CELLS | September 2023 | March 2026 | Allow | 29 | 1 | 0 | No | No |
| 18453712 | METHODS OF PRODUCING RPE CELLS | August 2023 | October 2024 | Allow | 14 | 2 | 0 | No | No |
| 18364151 | BACTERIA | August 2023 | May 2025 | Allow | 22 | 1 | 1 | No | No |
| 18275125 | CULTURE MEDIUM AND CULTURE METHOD FOR PRIMARY CELLS OF INTESTINAL CANCER | July 2023 | January 2026 | Allow | 29 | 1 | 0 | Yes | No |
| 18225360 | MEDIUM SUPPLEMENT TO INCREASE THE EFFICIENCY OF OOCYTE MATURATION AND EMBRYO CULTURE IN VITRO | July 2023 | November 2024 | Abandon | 16 | 1 | 0 | No | No |
| 18215601 | ANTIBIOTIC SUSCEPTIBILITY EVALUATION APPARATUS | June 2023 | December 2025 | Allow | 29 | 1 | 0 | No | No |
| 18027203 | CELLULAR MICROCOMPARTMENTS COMPRISING HUMAN CELLS UNDERGOING CARDIAC DIFFERENTIATION, TISSUES OBTAINED FROM SAID MICROCOMPARTMENTS AND USES THEREOF | June 2023 | January 2026 | Allow | 34 | 1 | 0 | No | No |
| 18214190 | BIOGAS COLLECTION APPARATUS AND METHOD OF USE | June 2023 | March 2026 | Allow | 33 | 1 | 0 | No | No |
| 18269001 | NEURAL STEM CELL-INDUCED DIFFERENTIAL MEDIUM AND INDUCTION DIFFERENTIATION METHOD | June 2023 | January 2026 | Allow | 31 | 1 | 0 | Yes | No |
| 18268639 | CELL CULTURE METHOD | June 2023 | August 2025 | Allow | 26 | 0 | 0 | Yes | No |
| 18137254 | SYSTEMS AND METHODS FOR STAINING OF BIOLOGICAL SAMPLES | April 2023 | June 2025 | Allow | 26 | 2 | 1 | No | No |
| 18303247 | METHODS, DEVICES, AND COMPUTER PROGRAM PRODUCTS FOR STANDARDIZING A FERMENTATION PROCESS | April 2023 | September 2025 | Allow | 28 | 1 | 1 | No | No |
| 18132087 | BONE DERIVED FIBERS AND OXYGENATED WOUND TREATMENTS | April 2023 | July 2025 | Allow | 27 | 3 | 1 | Yes | No |
| 18114861 | METHODS AND COMPOSITIONS TO MAINTAIN STEM CELL QUIESCENCE | February 2023 | November 2024 | Allow | 20 | 1 | 0 | No | No |
| 18113281 | ULTRA-HIGH DENSITY CELL BANKING METHODS | February 2023 | March 2026 | Allow | 37 | 3 | 0 | No | No |
| 18170669 | ORGAN/TISSUE DECELLULARIZATION, FRAMEWORK MAINTENANCE AND RECELLULARIZATION | February 2023 | February 2025 | Allow | 24 | 2 | 0 | No | No |
| 18110427 | Method for Tissue Sample Fixation | February 2023 | July 2024 | Allow | 17 | 1 | 0 | Yes | No |
| 18107951 | PROCESSING SYSTEM FOR PROCESSING SPECIMENS USING ACOUSTIC ENERGY | February 2023 | September 2024 | Allow | 20 | 1 | 1 | No | No |
| 18154461 | AMNION TISSUE GRAFTS AND METHODS OF PREPARING AND USING SAME | January 2023 | November 2024 | Allow | 22 | 2 | 0 | Yes | No |
| 18094770 | Compositions and Methods for Stabilizing Circulating Tumor Cells | January 2023 | June 2024 | Allow | 17 | 1 | 0 | No | No |
| 18014224 | Extracellular Vesicles (EVs) Derived from Mesenchymal Stromal Cells and Method for Obtaining Said EVs | January 2023 | January 2026 | Allow | 36 | 1 | 0 | No | No |
| 18068137 | Engineered Three-Dimensional Skin Tissues, Arrays Thereof, and Methods of Making the Same | December 2022 | November 2025 | Allow | 35 | 1 | 0 | Yes | No |
| 18010906 | TRANSPARENTIZING PRETREATMENT METHOD OF BIOLOGICAL SAMPLE HAVING SIZE OF AT MOST 1 MM, AND TRANSPARENTIZING METHOD OF BIOLOGICAL SAMPLE INCLUDING SAME | December 2022 | May 2025 | Allow | 29 | 1 | 1 | No | No |
| 18002101 | COMPOSITION FOR BONE REGENERATION COMPRISING METTL7A OVEREXPRESSING STEM CELLS, METHOD FOR PREPARING SAME, AND CELL THERAPY PRODUCT COMPRISING SAME | December 2022 | December 2025 | Allow | 36 | 1 | 0 | No | No |
| 18063600 | SYSTEMS AND METHODS FOR OPTIMIZED PATIENT SPECIFIC TISSUE ENGINEERING VASCULAR GRAFTS | December 2022 | June 2024 | Allow | 18 | 1 | 0 | No | No |
| 18075919 | METHODS AND MATERIALS FOR REDUCING VENOUS NEOINTIMAL HYPERPLASIA OF AN ARTERIOVENOUS FISTULA OR GRAFT | December 2022 | June 2024 | Allow | 18 | 1 | 0 | No | No |
| 17993343 | COMPOSITION AND METHOD FOR TREATING CANCER | November 2022 | May 2024 | Allow | 28 | 2 | 1 | Yes | No |
| 17973220 | SUSPENSION COMPOSITION FOR HEMATOLOGY ANALYSIS CONTROL | October 2022 | May 2025 | Allow | 30 | 2 | 0 | No | No |
| 17919453 | REGENERATIVE NONSTEROIDAL ANTI-INFLAMMATORY COMPOSITIONS, METHODS OF PRODUCTION, AND METHODS OF USE THEREOF | October 2022 | March 2026 | Abandon | 41 | 1 | 0 | No | No |
| 17961478 | TOPICAL COMPOSITION FOR USE IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | October 2022 | August 2024 | Abandon | 22 | 1 | 0 | No | No |
| 17937155 | METHODS OF INCREASING PROGENITOR CELL PRODUCTION | September 2022 | December 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17929052 | FIBROBLAST HAVING ENHANCED ERYTHROPOIETIN PRODUCTION ABILITY | September 2022 | November 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17822663 | CONTROLLED GROWTH OF MICROORGANISMS | August 2022 | January 2025 | Allow | 28 | 2 | 0 | No | No |
| 17881453 | METHODS AND COMPOSITIONS FOR CRYOPRESERVATION OF CELL THERAPIES | August 2022 | October 2025 | Allow | 38 | 2 | 1 | Yes | No |
| 17866804 | METHOD OF IN SITU REMEDIATION OF SOILS USING A BIOREMEDIATION COMPOSITION INCLUDING A TIME RELEASE MATERIAL | July 2022 | December 2024 | Allow | 29 | 1 | 1 | No | No |
| 17813192 | MESENCHYMAL STEM CELL-DERIVED EXTRACELLULAR VESICLES AND USES THEREOF FOR TREATING AND DIAGNOSING FIBROTIC DISEASES | July 2022 | August 2025 | Allow | 37 | 1 | 0 | Yes | No |
| 17865875 | ANTI-FIBROSIS AGENT AND METHOD OF PRODUCING EXTRACELLULAR VESICLE HAVING ANTI-FIBROSIS ACTION | July 2022 | September 2025 | Allow | 38 | 3 | 0 | Yes | No |
| 17864633 | ANGIOGENESIS AGENT AND METHOD OF PRODUCING EXTRACELLULAR VESICLE HAVING ANGIOGENESIS ACTION | July 2022 | September 2025 | Allow | 38 | 2 | 0 | Yes | No |
| 17792771 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ALZHEIMER'S AND USE THEREOF | July 2022 | March 2026 | Abandon | 44 | 0 | 1 | No | No |
| 17792397 | USE OF NOCARDIA RUBRA CELL WALL SKELETON IN REGENERATIVE MEDICINE | July 2022 | November 2025 | Allow | 41 | 1 | 0 | Yes | No |
| 17856085 | COMPOSITIONS AND METHODS OF PREPARING AIRWAY CELLS | July 2022 | April 2024 | Allow | 22 | 1 | 0 | No | No |
| 17844829 | System and Process for Increasing Protein Product Yield from Bacterial Cells | June 2022 | April 2024 | Allow | 22 | 1 | 0 | Yes | No |
| 17844198 | BUSINESS METHODS, PROCESSES AND SYSTEMS FOR COLLECTION, CRYOGENIC STORAGE AND DISTRIBUTION OF COSMETIC FORMULATIONS FROM AN OBTAINED STEM CELL BASED BIOLOGICAL MATERIAL | June 2022 | September 2024 | Abandon | 27 | 0 | 1 | No | No |
| 17826637 | METHODS AND SYSTEMS FOR RAPID CONTINUOUS FLOW PATHOGEN CELL LYSIS IN A MICROFLUIDIC CHANNEL | May 2022 | June 2024 | Allow | 25 | 1 | 0 | No | No |
| 17664856 | CELL THERAPIES AND METHODS OF TREATMENT FOR SMALL-VOLUME STROKE | May 2022 | July 2024 | Allow | 26 | 2 | 1 | No | No |
| 17748189 | COMPOSITIONS CAPABLE OF STIMULATING IMMUNITY TOWARDS TUMOR BLOOD VESSELS | May 2022 | April 2025 | Abandon | 35 | 0 | 1 | No | No |
| 17777856 | GENERATION OF KIDNEY GLOMERULAR SPECIFIC ENDOTHELIAL CELLS AND METHODS OF USE | May 2022 | September 2025 | Allow | 40 | 1 | 0 | Yes | No |
| 17774562 | COMPOSITION FOR PREVENTING OR TREATING RENAL DISEASES, COMPRISING EXOSOMES DERIVED FROM PRECURSOR CELLS OF INDUCED PLURIPOTENT STEM CELL-DERIVED MESENCHYMAL STEM CELLS | May 2022 | October 2025 | Allow | 42 | 1 | 0 | No | No |
| 17773556 | THERAPY FOR INTERSTITIAL CYSTITIS BY PLURIPOTENT STEM CELLS | April 2022 | August 2025 | Allow | 39 | 1 | 0 | No | No |
| 17658439 | ASEPTIC CELL PROCESSING AND PRODUCTION WITH NO CHEMICAL BIOCIDES | April 2022 | October 2024 | Allow | 30 | 2 | 0 | No | No |
| 17765881 | CHIMERIC ANTIGEN RECEPTOR SPECIFICALLY BINDING TO CD138, IMMUNE CELL EXPRESSING SAME, AND ANTICANCER USE THEREOF | April 2022 | December 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17710418 | COMPOSITIONS AND METHODS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | March 2022 | November 2025 | Allow | 44 | 1 | 1 | Yes | No |
| 17632752 | METHODS AND COMPOSITIONS FOR RECONSTITUTING MICROGLIA | February 2022 | November 2025 | Allow | 45 | 1 | 0 | Yes | No |
| 17587528 | METHODS AND COMPOSITIONS FOR MODULATING PD1 | January 2022 | February 2026 | Abandon | 49 | 1 | 1 | No | No |
| 17587685 | METHODS FOR ENHANCING LIFESPAN AND/OR TREATING CELLULAR PROLIFERATIVE DISORDERS BY TRANSPLANTATION | January 2022 | February 2026 | Allow | 48 | 1 | 1 | Yes | No |
| 17628011 | PREPARATIONS COMPRISING MESENCHYMAL STEM CELLS AND CANNABINOIDS AND METHODS OF THEIR USE | January 2022 | October 2024 | Allow | 33 | 1 | 0 | No | No |
| 17572227 | TRANSPARENT SKIN SAMPLE | January 2022 | May 2025 | Abandon | 41 | 3 | 0 | No | No |
| 17572330 | SLOW INTRAVENTRICULAR DELIVERY | January 2022 | May 2025 | Abandon | 40 | 2 | 0 | No | Yes |
| 17569634 | PLURIPOTENT STEM CELL MANUFACTURING SYSTEM AND METHOD FOR PRODUCING INDUCED PLURIPOTENT STEM CELLS | January 2022 | March 2025 | Abandon | 38 | 2 | 0 | No | No |
| 17623735 | IMMUNOTHERAPY TARGETING CELL SURFACE MARKER CD72 FOR THE TREATMENT OF B-CELL MALIGNANCIES | December 2021 | October 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17622288 | Production Method of (R)-Reticuline | December 2021 | March 2025 | Allow | 39 | 2 | 1 | Yes | No |
| 17419420 | CD7 CHIMERIC ANTIGEN RECEPTOR-MODIFIED NK-92MI CELL AND USE THEREOF | December 2021 | September 2025 | Abandon | 50 | 0 | 1 | No | No |
| 17550949 | METHODS FOR HARVESTING MICROALGAE | December 2021 | February 2024 | Abandon | 26 | 1 | 0 | Yes | No |
| 17542051 | INDOOR FOOD WASTE FERMENTATION AND RECYCLING PROCESS | December 2021 | February 2024 | Abandon | 26 | 1 | 0 | No | No |
| 17616489 | UNSPECIFIC PEROXYGENASE ENZYME VARIANTS FOR SELECTIVE FATTY ACID EPOXIDATION OR HYDROXYLATION | December 2021 | March 2025 | Allow | 39 | 1 | 1 | Yes | No |
| 17615540 | METHODS FOR TREATING METABOLIC DISORDERS BY TARGETING ADCY5 | November 2021 | January 2026 | Allow | 49 | 1 | 1 | No | No |
| 17456136 | CONTROLLED PRINTING OF A CELL SAMPLE FOR KARYOTYPING | November 2021 | November 2024 | Allow | 36 | 3 | 0 | No | No |
| 17612934 | NR4A SUPER-REPRESSORS AND METHODS OF USE THEREOF | November 2021 | December 2025 | Allow | 48 | 1 | 1 | Yes | No |
| 17527422 | IN VITRO GASTROINTESTINAL MODEL COMPRISING LAMINA PROPRIA-DERIVED CELLS | November 2021 | June 2025 | Abandon | 43 | 1 | 1 | No | No |
| 17610181 | METHODS AND MATERIALS FOR TREATING CARDIOVASCULAR DISEASES | November 2021 | October 2025 | Abandon | 47 | 3 | 0 | No | No |
| 17519655 | ENRICHMENT OF SURGICAL SPECIMENS FOR TUMOR TISSUE | November 2021 | March 2025 | Allow | 40 | 1 | 0 | No | No |
| 17608252 | ALKALINE PHOSPHATE-BASED ONCOLOGY TREATMENTS | November 2021 | January 2025 | Allow | 39 | 1 | 1 | No | No |
| 17608359 | DIFFERENTIALLY EXPRESSED IMMUNE CELL MICRORNAS FOR REGULATION OF PROTEIN EXPRESSION | November 2021 | July 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17607592 | ANTIGEN SPECIFIC CD19-TARGETED CAR-T CELLS | October 2021 | November 2025 | Allow | 49 | 1 | 1 | Yes | No |
| 17606167 | MEMBRANE PROTEASE-BASED METHODS FOR DETECTION OF BACTERIA | October 2021 | March 2025 | Allow | 41 | 1 | 1 | Yes | No |
| 17506831 | ENGINEERING MECHANICALLY FUNCTIONAL HUMAN CARTILAGE AND METHOD OF MAKING SAME | October 2021 | March 2024 | Allow | 29 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LANKFORD JR, LEON B.
With a 50.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 34.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner LANKFORD JR, LEON B works in Art Unit 1657 and has examined 464 patent applications in our dataset. With an allowance rate of 82.1%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 36 months.
Examiner LANKFORD JR, LEON B's allowance rate of 82.1% places them in the 54% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by LANKFORD JR, LEON B receive 1.96 office actions before reaching final disposition. This places the examiner in the 49% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by LANKFORD JR, LEON B is 36 months. This places the examiner in the 35% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +13.9% benefit to allowance rate for applications examined by LANKFORD JR, LEON B. This interview benefit is in the 52% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 29.8% of applications are subsequently allowed. This success rate is in the 57% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 52.7% of cases where such amendments are filed. This entry rate is in the 79% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 125.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 83% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 90.5% of appeals filed. This is in the 83% percentile among all examiners. Of these withdrawals, 68.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 65.6% are granted (fully or in part). This grant rate is in the 71% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 1.9% of allowed cases (in the 74% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.